Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Oncosec Medical (ONCS)

Oncosec Medical (ONCS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
OncoSec Announces Exclusive License Agreement for Cliniporator® Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intra-tumoral cancer immunotherapies, today announced that...

ONCS : 4.91 (-1.01%)
OncoSec Provides Highlights from Analyst & Investor Day and SITC 2020 and Announces KEYNOTE-695 Reaches Full Enrollment

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today provided highlights from its Analyst & Investor Day and Symposium held at the Society for Immunotherapy...

ONCS : 4.91 (-1.01%)
OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced new positive interim data from its KEYNOTE-695 registration-enabled Phase clinical trial...

ONCS : 4.91 (-1.01%)
OncoSec Hosting an Investor and Analyst Day Webinar Showcasing Positive KEYNOTE-695 Data in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that it will host an Investor and Analyst webinar on from – showcasing interim data from...

ONCS : 4.91 (-1.01%)
OncoSec to Present Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that it will present new positive interim data from its KEYNOTE-695 registration-enabled...

ONCS : 4.91 (-1.01%)
OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug...

ONCS : 4.91 (-1.01%)
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intra-tumoral cancer immunotherapies, today announced that , Ph.D. joined...

ONCS : 4.91 (-1.01%)
OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO™ and Its Gene Delivery Platform

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intratumoral cancer immunotherapies, today announced  the issuance of a...

ONCS : 4.91 (-1.01%)
OncoSec Announces Initiation of a Phase 2 Study at the Moffitt Cancer Center to Evaluate the Combination of TAVO plus OPDIVO® as Neoadjuvant Therapy for Melanoma

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced the commencement of...

ONCS : 4.91 (-1.01%)
OncoSec to Present at the LD 500 Virtual Conference on September 2, 2020

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that , President and...

ONCS : 4.91 (-1.01%)
OncoSec Medical Incorporated Announces Pricing of Public Offering

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that in connection with its previously announced offering of common stock, it has entered...

ONCS : 4.91 (-1.01%)
OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that it intends to offer and sell shares of its common stock in a public offering. The offering...

ONCS : 4.91 (-1.01%)
OncoSec to Present at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that , President and...

ONCS : 4.91 (-1.01%)
OncoSec Set to Join Russel Microcap® Index

and , /PRNewswire/ -- (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced the Company is set to join the Russell Microcap Index at the conclusion of the...

ONCS : 4.91 (-1.01%)
OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II

and , /PRNewswire/ --(Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today presented new data further demonstrating the power of OncoSec's next-generation interleukin-12...

ONCS : 4.91 (-1.01%)
OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO™ and KEYTRUDA® Plus Chemotherapy

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that, based upon tumor...

MRK : 80.06 (-0.10%)
ONCS : 4.91 (-1.01%)
OncoSec to Present at Virtual Summer Investor Summit

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that , President and...

ONCS : 4.91 (-1.01%)
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th

The Virtual Summer Summit will take place on June 9-12, connecting 47 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below...

ACCO : 8.11 (-3.11%)
ALIM : 4.74 (+1.94%)
ANVS : 5.78 (+5.47%)
AQB : 4.16 (+4.52%)
ARTL : 0.5649 (+1.69%)
AVLNF : 0.0650 (-0.91%)
BLCM : 3.11 (+6.14%)
NDRA : 0.8353 (+0.70%)
EFOI : 4.96 (+3.55%)
EQ : 4.91 (-3.54%)
EXROF : 3.5500 (+5.34%)
HL : 4.82 (+2.55%)
HSII : 26.96 (+0.90%)
HSDT : 0.3903 (-2.35%)
HGBL : 1.5900 (-1.85%)
IPWR : 9.00 (-3.02%)
LINC : 6.44 (-0.46%)
MBII : 1.1600 (unch)
MLSS : 1.7700 (+1.14%)
MYSZ : 1.1600 (+0.69%)
NBEV : 3.41 (+0.29%)
ONCS : 4.91 (-1.01%)
OGEN : 0.3941 (+2.10%)
SFE : 6.60 (+2.64%)
SLS : 3.55 (+12.34%)
PIXY : 2.49 (-0.80%)
SGLB : 2.89 (+13.33%)
SOTK : 4.2000 (unch)
TNXP : 0.5520 (-2.13%)
TGA : 0.5346 (+8.77%)
URG : 0.5400 (+6.59%)
OncoSec Strengthens IP Portfolio with Three New Patents Covering TAVO™ and Its Electroporation Gene Delivery System

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced Notices of Allowance...

ONCS : 4.91 (-1.01%)
OncoSec to Present Two Late-Breaking Pre-Clinical Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II

and , /PRNewswire/ -- (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that it will present new pre-clinical data demonstrating the utility of OncoSec's...

ONCS : 4.91 (-1.01%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar